Sector News

Sun Pharma completes GSK’s opiates business acquisition in Australia

September 1, 2015
Life sciences

Following the successful completion of its deal to acquire GSK’s opiates business in Australia, Sun Pharmaceutical Industries Ltd has begun the process of integration of the acquired business. This deal, first announced in March 2015, fortifies Sun Pharma’s global position with two opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.

Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialised team to drive business growth. Opiates are any of the opioid analgesic alkaloids found as natural products in the opium poppy plant, Papaver somniferum.

The opiates acquisition allows Sun Pharma to significantly expands its narcotics raw material (NRM) market share; enhance opiate alkaloids portfolio & depth in global opiates market; and strengthen its strategic position in the global opiates business.

Anil Kumar Jain, CEO – API business, Sun Pharma, said, “The successful completion of this acquisition enables us to leverage our unique position in the global opiates business by capitalising our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation.”

Source: Business Standard

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend